Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.70 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.50 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.50 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1834847 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL2996593 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL10607854 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL10566561 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL10605202 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL8527626 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL1835536 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL9117095 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL251104 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL28914358 | 1.00 | USP2 (0.80) | USP2HTTLPAR5SPHK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2010030730-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | USP2 1100/4885HTT 2221/4885LPAR5 119/4885 |
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | USP2 4459/4885HTT 1006/4885LPAR5 149/4885 |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | LIPA, SGMS2, SGMS1 | USP2 4459/4885HTT 1006/4885LPAR5 149/4885 |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | USP2 4459/4885HTT 1006/4885LPAR5 149/4885 |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | USP2 4459/4885HTT 1006/4885LPAR5 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.